Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833482 · ClinicalTrials.gov registry record · Phase 1
Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 185
- Enrollment target
NCT00833482 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 185 participants.
The verdict
NCT00833482, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 185 participants
- Enrollment target
Study Summary
This study assesses the effects of voriconazole, 200 mg, administered twice daily (BID), on the steady-state pharmacokinetics of atazanavir administered as atazanavir/ritonavir, 300/100 mg once daily (QD), in healthy participants with functional CYP2C19 alleles. The study also reviews the effects of atazanavir/ritonavir, 300/100 mg QD, on the pharmacokinetics of voriconazole, 200 mg, BID in healthy participants with functional CYP2C19 alleles.
Interventions
- DRUG Ritonavir
- DRUG Atazanavir
- DRUG Voriconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833482
The ClinicalTrials.gov registry entry for NCT00833482 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ritonavir is the first listed.
NCT00833482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00833482 about?
NCT00833482 is a clinical study titled "Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants". This study assesses the effects of voriconazole, 200 mg, administered twice daily (BID), on the steady-state pharmacokinetics of atazanavir administered as atazanavir/ritonavir, 300/100 mg once daily (QD), in healthy participants with functional CYP2C19 alleles. The study also reviews the effects of...
What is the current status of trial NCT00833482?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 185 participants. The study started on 2009-09. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00833482?
The interventions under investigation include: Ritonavir (DRUG), Atazanavir (DRUG), Voriconazole (DRUG).
Who is sponsoring clinical trial NCT00833482?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.